Replicon RNA Influenza Vaccine
Influenza Prevention
Preclinical/DevelopmentPartnership Development with VLPT Japan and Denka
Key Facts
Indication
Influenza Prevention
Phase
Preclinical/Development
Status
Partnership Development with VLPT Japan and Denka
Company
About BIKEN Group
Japanese specialty vaccine organization developing and manufacturing traditional and novel RNA-based vaccines for infectious diseases.
View full company profileTherapeutic Areas
Other Influenza Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA-based Broad Flu Vaccine | Micron Biomedical | Pre-clinical |
| CaPtivaX Nasal Influenza Vaccine | CaPtivate Pharmaceuticals | Pre-clinical |
| Next-Generation Influenza Vaccines | Fluart Innovative Vaccines | Not Disclosed |
| HD-MAP Influenza Vaccine | Vaxxas | Phase 2/3 |
| IRT Platform (e.g., Influenza) | Biological Mimetics | Research/Pre-clinical |
| Innovative Influenza Vaccine | Livzon Pharmaceutical | Phase 1 |
| CS-2606 mRNA Multi-valent Influenza Vaccine | CanSino Biologics | Pre-clinical |